var data={"title":"Oxybutynin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxybutynin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6698?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxybutynin-drug-information\" class=\"drug drug_general\">see &quot;Oxybutynin: Drug information&quot;</a> and <a href=\"topic.htm?path=oxybutynin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxybutynin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204694\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ditropan XL;</li>\n      <li>Gelnique;</li>\n      <li>Gelnique Pump;</li>\n      <li>Oxytrol;</li>\n      <li>Oxytrol For Women [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204695\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ditropan XL;</li>\n      <li>Gelnique;</li>\n      <li>Oxybutyn;</li>\n      <li>Oxybutynine;</li>\n      <li>Oxytrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060756\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antispasmodic Agent, Urinary</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060750\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=oxybutynin-drug-information\" class=\"drug drug_general\">see &quot;Oxybutynin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neurogenic/Overactive bladder: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &le;5 years: Limited data available:  0.1 to 0.2 mg/kg/dose 2 to 3 times daily; maximum dose: 5 mg/dose (Buyse 1998a; Buyse 1998b; Ferrara 2001; Kleigman 2016); one retrospective study  reported doses as high 0.2 mg/kg/dose every 6 hours (Kaefer 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;5 years and Adolescents: Initial: 5 mg twice daily, increase as necessary up to 5 mg 3 times daily; adult maximum dose: 5 mg 4 times daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: Children &ge;6 years and Adolescents: Initial: 5 mg once daily;  adjust dose as needed in 5 mg increments at weekly intervals; maximum daily dose: 20 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intravesical: Limited data available: Infants, Children, and Adolescents: 0.2 mg/kg/dose twice daily at 8 to 12 hour intervals; maximum dose: 5 mg/dose (Amark 1998; Buyse 1998a; Buyse 1998b; Ferrara 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Overactive bladder, idiopathic:</b> Limited data available: Transdermal: Children &ge;4 years and Adolescents: Apply one 3.9 mg/day patch twice weekly (every 3 to 4 days); dosing based on a retrospective study of 35 children (mean age: 8 years; range: 4 to 16 years) with idiopathic overactive bladder; most patients (97%) reported good symptom control; skin irritation at the application site was reported in 35% of patients with 20% resulting in discontinuation of therapy; no other significant side effects were reported (Gleason 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Overactive bladder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 5 mg 2 to 3 times daily; maximum: 5 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 5 to 10 mg once daily; adjust dose in 5 mg increments at weekly intervals; maximum: 30 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical gel: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gelnique 3%: Apply 3 pumps (84 mg) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gelnique 10%: Apply contents of 1 sachet (100 mg/g) once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Apply one 3.9 mg/day patch twice weekly (every 3 to 4 days) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204669\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gelnique: 3% (92 g [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gelnique: 10% (1 g) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gelnique Pump: 10% (30 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Twice Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxytrol: 3.9 mg/24 hr (1 ea, 2 ea [DSC], 4 ea [DSC], 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxytrol For Women: 3.9 mg/24 hr (4 ea, 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ditropan XL: 5 mg, 10 mg, 15 mg [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204653\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060759\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May be administered with or without food. Extended release tablets must be swallowed whole with liquid; do not chew, divide, or crush; take at approximately the same time each day. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Topical gel: For topical use only. Apply to clean, dry, intact skin on abdomen, thighs, or upper arms/shoulders. Wash hands after use. Cover treated area with clothing after gel has dried to prevent transfer of medication to others. Do not bathe, shower, or swim until 1 hour after gel applied. Do not apply to recently shaved skin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Gelnique 3% pump:</i> Prior to initial use, press pump 4 times to prime pump; discard any gel dispensed from pump during priming. Rotate application sites to avoid skin irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Gelnique 10% sachet:</i> Rotate site; do not apply to same site on consecutive days. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal: Apply to clean dry intact skin on the abdomen, hip, or buttock. Rotate site of application with each administration and avoid application to the same site within 7 days. Wear patch under clothing; do not expose to sunlight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intravesical: Immediately prior to administration crush the appropriate number of immediate release tablets based on dose and dissolve in sterile water or saline to a final concentration of 5 mg/mL (Kennelly 2010); administer directly into the bladder after emptying via catheter (Buyse 1998a; Buyse 1998b)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204689\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablet and syrup: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture and humidity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical gel: Store at 20&deg;C to 25&deg;C (68&deg;C to 77&deg;F). Protect from moisture and humidity. Keep away from open flame. Do not store outside the sealed pouch or pump dispenser; apply immediately after removal from the protective pouch or once contents expelled from pump dispenser. Discard used sachets such that accidental application or ingestion by children, pets, or others are avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture and humidity. Do not store outside the sealed pouch; apply immediately after removal from the protective pouch. Discard used patches such that accidental application or ingestion by children, pets, or others is avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060758\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablets, oral solution: Relief of bladder spasms associated with voiding in patients with uninhibited and reflex neurogenic bladder (ie, urgency, frequency, urinary leakage, urge incontinence, dysuria) (FDA approved in ages &gt;5 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablets: Treatment of symptoms of detrusor overactivity associated with a neurological condition (FDA approved in ages &ge;6 years); treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical gel (Gelnique): Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oxytrol: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oxytrol for Women: Treatment of overactive bladder in women (OTC product: FDA approved in ages &ge;18 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204742\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oxybutynin may be confused with OxyCONTIN</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ditropan may be confused with Detrol, diazePAM, Diprivan, dithranol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Oxybutynin is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204740\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased blood pressure, edema, flushing, increased blood pressure, palpitations, peripheral edema, sinus arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Confusion, dizziness, drowsiness, falling, fatigue, flank pain, headache, insomnia, nervousness, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention, increased serum glucose, increased thirst</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, coated tongue, constipation, diarrhea, dysgeusia, dyspepsia, eructation, flatulence, gastroesophageal reflux disease, nausea, upper abdominal pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Cystitis, dysuria, increased post-void residual urine volume, pollakiuria, urinary hesitancy, urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, eye irritation, keratoconjunctivitis sicca, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Asthma, bronchitis, cough, dry nose, dry throat, hoarseness, nasal congestion, nasopharyngitis, oropharyngeal pain, pharyngolaryngeal pain, sinus congestion, sinus headache, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Topical gel:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation, viral gastroenteritis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site dermatitis, application site pruritus, application site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Transdermal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Macular eruption (application site)</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Gastrointestinal: Constipation, diarrhea, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema, application site pruritus, application site rash, application site vesicles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:0em;\">Rare but important or life-threatening: Agitation, anaphylaxis, angioedema, anorexia, cardiac arrhythmia, chest discomfort, confusion, cycloplegia, decreased gastrointestinal motility, decreased lactation, delirium, dizziness, drowsiness, dysphagia, facial edema, frequent bowel movements, glaucoma, hallucination, headache, hot flash, hypersensitivity reaction, hypertension, hypohidrosis, impotence, memory impairment, mydriasis, prolonged Q-T interval on ECG, psychotic reaction, seizure, skin rash, tachycardia, urticaria, voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204675\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to oxybutynin or any component of the formulation; patients with or at risk for uncontrolled narrow-angle glaucoma, urinary retention, gastric retention or conditions with severely decreased GI motility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use if you have pain or burning when urinating, blood in urine, unexplained lower back or side pain, cloudy or foul-smelling urine; in males; age &lt;18 years; only experience accidental urine loss when cough, sneeze, or laugh; diagnosis of urinary or gastric retention; glaucoma; hypersensitivity to oxybutynin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe GI conditions; myasthenia gravis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204657\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema/hypersensitivity reactions: May cause hypersensitivity, including anaphylaxis and angioedema. Cases of angioedema involving the face, lips, tongue, and/or larynx have been reported with oral oxybutynin; some cases have occurred after a single dose. Discontinue immediately if tongue, hypopharynx, or larynx is involved; promptly initiate appropriate management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Anticholinergics may cause agitation, confusion, drowsiness, dizziness, hallucinations, headache, somnolence, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction or discontinuation should be considered if CNS effects occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heat prostration: May increase the risk of heat prostration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bladder flow obstruction: Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with CAD, heart failure, hypertension, and/or cardiac arrhythmias; may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: Use with caution in patients with dementia treated with cholinesterase inhibitors; may aggravate symptoms of disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disorders: Use with caution in patients with decreased GI motility or GI obstructive disorders; may increase the risk of gastric retention. Use with caution in patients with ulcerative colitis, intestinal atony, pyloric stenosis, gastroesophageal reflux, or with medications that may cause or exacerbate esophagitis (eg, bisphosphonates). In patients with ulcerative colitis, use may decrease gastric motility to the point of increasing the risk of paralytic ileus or toxic megacolon.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with treated angle-closure glaucoma; may exacerbate condition; use is contraindicated with uncontrolled narrow-angle glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (limited experience).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hiatal hernia: Use with caution in patients with hiatal hernia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Avoid use in patients with myasthenia gravis; may exacerbate condition. Discontinue therapy if signs/symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Use with caution in patients with autonomic neuropathy; may aggravate symptoms of decreased GI motility.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; may aggravate symptoms of disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture; may cause urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (limited experience).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release formulation: The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Topical gel: To minimize transferring medication to others, cover treatment area with clothing after gel has dried. Discontinue use if skin irritation occurs. Contains ethanol; do not expose to open flame or smoking until gel has dried.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC labeling: Other causes of frequent urination (UTI, diabetes, early pregnancy, other serious conditions) may need to be considered prior to use. Patients should contact a health care provider if symptoms do not improve within 2 weeks of initial use or for new or worsening symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535368\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intravesical administration of oxybutynin may be used for the treatment of neurogenic bladder in patients intolerant to or refractory to oral oxybutynin. Several studies have suggested a reduced incidence of anticholinergic side effects with intravesical administration compared to those observed with oral therapy (Buyse 1998b; Guerra 2008). However, one study showed a higher incidence of CNS side effects (eg, hallucination, drowsiness, and cognitive impairment) in children receiving intravesical oxybutynin compared to those receiving oral oxybutynin at comparable doses.  It is speculated that the higher plasma concentrations associated with intravesical administration compared to oral is responsible for this effect (Ferrara 2001); closely monitor patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204730\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204662\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12665&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Oxybutynin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Oxybutynin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204665\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204677\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events  were not observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204656\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Direct antispasmodic effect on smooth muscle, also inhibits the action of acetylcholine on smooth muscle (exhibits <sup>1</sup>/<sub>5</sub> the anticholinergic activity of atropine, but has 4-10 times the antispasmodic activity); does not block effects at skeletal muscle or at autonomic ganglia; increases bladder capacity, decreases uninhibited contractions, and delays desire to void, therefore, decreases urgency and frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204674\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: Immediate release: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Immediate release: 3 to 6 hours; Extended release: 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Oral: Immediate release: 6 to 10 hours; Extended release: Up to 24 hours; Transdermal 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapid and well absorbed; Transdermal: High</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: V<sub>d</sub>: 193 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99% primarily to alpha<sub>1</sub>-acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4; Oral: High first-pass metabolism; forms active and inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Immediate release: 6% (range: 1.6% to 10.9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~2 hours (parent drug), 7 to 8 hours (metabolites); Oral: Immediate release: ~2 to 3 hours; Extended release: ~13 hours; Transdermal: 64 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Immediate release: ~60 minutes; Extended release: 4 to 6 hours; Transdermal: 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;0.1% as metabolites and unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204676\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Gelnique Pump Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (30 g): $452.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Gelnique Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (1 g): $15.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Oxytrol For Women Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.9 mg/24 hrs (4): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Oxytrol Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.9 mg/24 hrs (1): $97.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Oxybutynin Chloride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (473 mL): $51.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Ditropan XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $762.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $763.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $782.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Oxybutynin Chloride ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $328.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $328.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $336.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Oxybutynin Chloride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $76.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204680\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ao Ning (CN);</li>\n      <li>Butyn (PK);</li>\n      <li>Cystrin (GB, IE);</li>\n      <li>Delifon (CO);</li>\n      <li>Ditropan (AE, AR, AT, AU, BE, CH, CY, CZ, ES, FI, FR, GB, GR, HN, HU, IE, IT, JO, KR, KW, LB, LU, MT, PL, PT, SE, TW);</li>\n      <li>Ditropan XL (BB);</li>\n      <li>Diutropan (TH);</li>\n      <li>Dresplan (ES);</li>\n      <li>Dridase (DE, NL);</li>\n      <li>Driptane (EE, HR, LB, LV, PH, RU, VN);</li>\n      <li>Dryptan (UA);</li>\n      <li>Frenurin (BR);</li>\n      <li>Gradual (UY);</li>\n      <li>Inprax (MX);</li>\n      <li>Kentera (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IT, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR);</li>\n      <li>Kentera Patch (GB, IE);</li>\n      <li>Lenditro (ZA);</li>\n      <li>Lyrinel (IL, MX, TH);</li>\n      <li>Lyrinel Oros SR (KR);</li>\n      <li>Lyrinel XL (GB, IE);</li>\n      <li>Mutum (EC);</li>\n      <li>Mutum CR (EC);</li>\n      <li>Nefryl (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Neoxy Tape (JP);</li>\n      <li>Newin (TW);</li>\n      <li>Novitropan (IL);</li>\n      <li>Obutin (SG);</li>\n      <li>Odranal (CL);</li>\n      <li>Oxyban (TW);</li>\n      <li>Oxyspas (LK);</li>\n      <li>Oxytrol (AU, NZ);</li>\n      <li>Pollakisu (JP);</li>\n      <li>Reteven (PE, VE);</li>\n      <li>Socliden (PY);</li>\n      <li>Sybutin (UA);</li>\n      <li>Tavor (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tropan (IN);</li>\n      <li>Uricon CR (BD);</li>\n      <li>Urihexal (ZA);</li>\n      <li>Uroflax (PY);</li>\n      <li>Uropan (TR);</li>\n      <li>Uroxal (HU);</li>\n      <li>Voxytane (MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amark P, Eksborg S, Juneskans O, Bussman G, Palm C. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. <i>Br J Urol</i>. 1998;82(6):859-864.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9883225 /pubmed\" target=\"_blank\" id=\"9883225 \">9883225 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buyse G, Verpoorten C, Vereecken R, Casaer P. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. <i>J Urol</i>. 1998a;160(3 Pt 2):1084-1087.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9719281/pubmed\" target=\"_blank\" id=\"9719281\">9719281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buyse G, Waldeck K, Verpoorten C, Bj&ouml;rk H, Casaer P, Andersson KE. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. <i>J Urol</i>. 1998b;160(3 Pt 1):892-896.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9720583 /pubmed\" target=\"_blank\" id=\"9720583 \">9720583 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrara P, D'Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. <i>BJU Int</i>. 2001;87(7):674-678.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/11350411 /pubmed\" target=\"_blank\" id=\"11350411 \">11350411 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelnique 3% gel (oxybutynin) [prescribing information]. Parsippany, NJ: Watson Pharma, Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelnique 10% gel (oxybutynin) [prescribing information]. Parsippany, NJ: Watson Pharma, Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gleason JM, Daniels C, Williams K, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. <i>J Pediatr Urol</i>. 2014;10(4):753-757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/24477421 /pubmed\" target=\"_blank\" id=\"24477421 \">24477421 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humphreys MR and Reinberg YE, &quot;Contemporary and Emerging Drug Treatments for Urinary Incontinence in Children,&quot; <i>Paediatr Drugs</i>, 2005, 7(3):151-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/15977961/pubmed\" target=\"_blank\" id=\"15977961\">15977961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. <i>J Urol</i>. 1999;162(3 Pt 2):1068-1071.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/10458433/pubmed\" target=\"_blank\" id=\"10458433\">10458433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kennelly MJ. A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. <i>Rev Urol</i>. 2010;12(1):12-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/20428289 /pubmed\" target=\"_blank\" id=\"20428289 \">20428289 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxybutynin extended release tablet (oxybutynin) [prescribing information]. Pulaski, TN: AvKARE, Inc; March 2016. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxybutynin solution (oxybutynin) [prescribing information]. Huntsaville, AL: Qualitest Pharmaceuticals; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxybutynin tablet (oxybutynin) [prescribing information]. Sellersville, PA; Teva Pharmaceuticals USA; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxytrol for Women transdermal patch (oxybutynin) [prescribing information]. Whippany, NJ: Bayer Healthcare LLC; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxytrol transdermal patch (oxybutynin) [prescribing information]. Parsippany, NJ: Watson Pharma, Inc; July 2015. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12665 Version 198.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204694\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F204695\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060756\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060750\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204669\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F204653\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060759\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F204689\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060758\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F204742\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204740\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204675\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204657\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535368\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F204730\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204662\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204665\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204677\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204656\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F204674\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F204676\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F204680\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12665|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxybutynin-drug-information\" class=\"drug drug_general\">Oxybutynin: Drug information</a></li><li><a href=\"topic.htm?path=oxybutynin-patient-drug-information\" class=\"drug drug_patient\">Oxybutynin: Patient drug information</a></li></ul></div></div>","javascript":null}